Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
QMS Medical Allied ServicesNSE:QMSMEDI -0.47%72 Peter Lynch Fair Value is ₹41.15 as of Aug. 20, 2026, which is 100% below its 10-year median of 1.28. GuruFocus rates NSE:QMSMEDI with a GF Score™ of 72/100 and a GF Value™ of ₹121.32 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 150 Medical Devices & Instruments companies, QMS Medical Allied Services ranks worse than 86.67% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, QMS Medical Allied Services's PEG is 1. QMS Medical Allied Services's 5-Year TTM EBITDA Growth Rate is 7.62.
QMS Medical Allied Services's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5.40. Therefore, the Peter Lynch Fair Value for today is ₹41.15.
The historical rank and industry rank for QMS Medical Allied Services's Peter Lynch Fair Value or its related term are showing as below:
NSE:QMSMEDI'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.81 Med: 1.28 Max: 3.36
Current: 3.27
During the past 7 years, the highest Price to Peter Lynch Fair Value Ratio of QMS Medical Allied Services was 3.36. The lowest was 0.81. And the median was 1.28.
NSE:QMSMEDI's Price-to-Peter-Lynch-Fair-Value is ranked worse than 86.67% of 150
companies
in the Medical Devices & Instruments industry
Industry Median: 1.44
vs NSE:QMSMEDI: 3.27
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
QMS Medical Allied Services (NSE:QMSMEDI) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 7.62 instead of 15 in this case.
QMS Medical Allied Services's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
134.60
/
41.15
=
3.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QMS Medical Allied Services Peter Lynch Fair Value Related Terms
QMS Medical Allied Services Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QMS Medical Allied Services Peter Lynch Fair Value Chart
NSE:QMSMEDI vs ISRG, BDX, MDLN: Peter Lynch Fair Value Comparison
For the Medical Instruments & Supplies subindustry, QMS Medical Allied Services's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QMS Medical Allied Services Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, QMS Medical Allied Services's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where QMS Medical Allied Services's Price-to-Peter-Lynch-Fair-Value falls into.
QMS Medical Allied Services's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was ₹5.40.
* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of ₹41.15 mean?
QMS Medical Allied Services (NSE:QMSMEDI) has a Peter Lynch Fair Value of ₹41.15 as of Aug. 20, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on QMS Medical Allied Services and its competitors. This is 3115% above median its historical median of 1.28. Over the past decade, QMS Medical Allied Services' Peter Lynch Fair Value has ranged from 0.81 to 3.36. According to the industry distribution chart, QMS Medical Allied Services ranks #130 out of 150 companies in the Medical Devices & Instruments industry, placing it in the top 86.7%.
Is QMS Medical Allied Services' Peter Lynch Fair Value too high?
QMS Medical Allied Services' current Peter Lynch Fair Value of ₹41.15 is 3115% above median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 3.36. Based on the distribution chart, QMS Medical Allied Services ranks #130 out of 150 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, QMS Medical Allied Services has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does QMS Medical Allied Services' Peter Lynch Fair Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, QMS Medical Allied Services ranks #130 out of 150 companies for Peter Lynch Fair Value. This places QMS Medical Allied Services in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.44. Historically, QMS Medical Allied Services' own Peter Lynch Fair Value has ranged from 0.81 to 3.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.44, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on QMS Medical Allied Services and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QMS Medical Allied Services's current Peter Lynch Fair Value is ₹41.15, which is 3115% above median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QMS Medical Allied Services stock overvalued right now?
Based on GuruFocus' analysis, QMS Medical Allied Services (NSE:QMSMEDI) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹121.32, compared to a current price of ₹134.60 — trading 10.9% above its estimated fair value. The current Peter Lynch Fair Value is ₹41.15, which is 3115% above median its 10-year median of 1.28. QMS Medical Allied Services' overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For QMS Medical Allied Services (NSE:QMSMEDI), the current Peter Lynch Fair Value is ₹41.15 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is QMS Medical Allied Services (NSE:QMSMEDI) Overvalued in 2026?
Based on GuruFocus' analysis, QMS Medical Allied Services stock appears to be overvalued.
The current stock price of ₹134.60 is trading 10.9% above its estimated GF Value™ of ₹121.32.
GuruFocus considers QMS Medical Allied Services to be Modestly Overvalued.
Key valuation signals for NSE:QMSMEDI:
Peter Lynch Fair Value: ₹41.15 (3115% above median its 10-year median of 1.28)
GF Value™: ₹121.32 vs. price of ₹134.60 (10.9% above fair value)
No single metric tells the full story. See the NSE:QMSMEDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
QMS Medical Allied Services Ltd is engaged in the marketing and distribution of a wide range of medical products as well as medical education services. The company's products are sold under brand name "QDevices" and also manage the distribution for other brands such as 3M, Heine, Rossmax and others. It offers medical products such as Blood Pressure Monitors, Glucose Monitoring Kits and strips, Dental Products, Personal protection kits eg-PPE kits, Infection prevention, Stethoscope and Oxygen Concentrator.
72GF Score
Get the complete analysis for NSE:QMSMEDI
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QMSMEDI has been successfully added to your 
